BioVie posts corporate presentation spotlighting bezisterim longevity-focused therapy pipeline

BioVie Inc. Class A

BioVie Inc. Class A

BIVI

0.00
  • BioVie highlighted bezisterim (formerly NE3107) as its lead oral small molecule, positioned as a TNFα modulator with CNS penetration.
  • Topline data targeted for its Parkinson’s Phase 2b trial in Summer 2026; Long COVID exploratory Phase 2 readout targeted for late Summer 2026.
  • Development plans hinge on financing, including an ascites Phase 3 launch and a new once-daily bezisterim Alzheimer’s Phase 3 program.
  • Parkinson’s strategy emphasizes addressing motor symptoms alongside inflammation and insulin resistance, supported by earlier Phase 2 signals and preclinical data.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioVie Inc. published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.